L-dopa-induced dyskinesias (LIDs) are a serious complication of L-dopa therapy for Parkinson's disease. Emerging evidence indicates that the nicotinic cholinergic system plays a role in LIDs, although the pathways and mechanisms are poorly understood. Here we used optogenetics to investigate the role of striatal cholinergic interneurons in LIDs. Mice expressing cre-recombinase under the control of the choline acetyltransferase promoter (ChAT-Cre) were lesioned by unilateral injection of 6-hydroxydopamine. AAV5-ChR2-eYFP or AAV5-control-eYFP was injected into the dorsolateral striatum, and optical fibers implanted. After stable virus expression, mice were treated with L-dopa. They were then subjected to various stimulation protocols for 2 h and LIDs rated. Continuous stimulation with a short duration optical pulse (1-5 ms) enhanced LIDs. This effect was blocked by the general muscarinic acetylcholine receptor (mAChR) antagonist atropine indicating it was mAChR-mediated. By contrast, continuous stimulation with a longer duration optical pulse (20 ms to 1 s) reduced LIDs to a similar extent as nicotine treatment (~50%). The general nicotinic acetylcholine receptor (nAChR) antagonist mecamylamine blocked the decline in LIDs with longer optical pulses showing it was nAChR-mediated. None of the stimulation regimens altered LIDs in control-eYFP mice. Lesion-induced motor impairment was not affected by optical stimulation indicating that cholinergic transmission selectively regulates LIDs. Longer pulse stimulation increased the number of c-Fos expressing ChAT neurons, suggesting that changes in this immediate early gene may be involved. These results demonstrate that striatal cholinergic interneurons play a critical role in LIDs and support the idea that nicotine treatment reduces LIDs via nAChR desensitization.
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Introduction
A major limitation of L-dopa therapy for Parkinson's disease is the development of LIDs (Huot et al., 2013; Iravani et al., 2012; Meissner et al., 2011; Obeso et al., 2010; Schapira and Jenner, 2011) . These involuntary abnormal movements arise in the majority of patients with continued L-dopa use and can be debilitating. The only drug available for the treatment of LIDs is amantadine, which has variable efficacy, response durability and tolerability (Crosby et al., 2003; Luginger et al., 2000; Rodnitzky and Narayanan, 2014; Thomas et al., 2004) . Numerous studies over the last three decades show that alterations in the dopaminergic, serotonergic, glutamatergic, GABAergic, noradrenergic, histaminergic and opioid systems are involved in LIDs; however, identification of clinical therapies targeting these systems has proved elusive (Blandini and Armentero, 2012; Cenci, 2007; Gasparini et al., 2013; Huot et al., 2013; Iravani et al., 2012; Lim et al., 2015; Rylander, 2012) .
A novel target that has recently attracted attention is the striatal cholinergic system. The rationale is based on several lines of evidence including studies showing a close anatomical overlap between striatal dopaminergic nerve terminals and cholinergic interneurons (Lim et al., 2014; Zhou et al., 2002) . Cholinergic interneurons make up 1-3% of striatal neurons and extend large and dense axonal arbors throughout the striatum that allow them to play a pivotal role in the control of striatal function (Bonsi et al., 2011; Zhou et al., 2002) . These neurons fire action potentials at a rate of 5-10 Hz in a variable but ongoing manner that includes single spiking and rhythmic bursting patterns (Aosaki et al., 1995; Raz et al., 1996; Wilson et al., 1990) . This constant activity ensures a sufficient level of endogenous ACh to tonically activate mAChRs and nAChRs to regulate GABAergic, dopaminergic and glutamate signaling (Quik and Wonnacott, 2011) .
Alterations in cholinergic signaling and its functional interplay with the dopaminergic, GABAergic and glutamatergic systems in the striatum are implicated in movement disorders such as LIDs. Accumulating studies show that nAChR agonists and antagonists reduce LIDs in rodent and
